The "Rate Shock" Myth
As Affordable Care Act opponents continue grasping at straws to find fault with the law, an assertion perpetuated by the insurance industry that the ACA’s coverage expansions will significantly increase premiums has gained prominence.
Cross Post: Potential Costs and Challenges in Boston
With much of the country still reeling from the Boston marathon bombings, many of the victims – as well as their families and friends – have already begun the long road to recovery.
Scorecard Shows U.S. Medical Schools Continue to Make Progress in Pharmaceutical Conflict-of-Interest Policies
The American Medical Student Association released its 2013 PharmFree Scorecard this month, continuing to pressure and encourage medical schools to improve their policies on conflicts of interest and interactions with industry.
From the Feds Down to the States: Using Navigators to Promote Health Equity
HHS recently released the cooperative agreement funding opportunity for organizations interested in serving as Navigators in states with a Partnership or Federally Facilitated Exchange.
The Fine Print
Building new ways of delivering care to the millions of older adults and people with disabilities who are eligible for both Medicare and Medicaid (dual eligibles) is a daunting task. There is much work to be done.
Spring NAIC Meeting: Insurance Commissioners Take Houston
This past weekend, insurance commissioners and their staff, along with insurance companies, brokers, other industry representatives, and a few intrepid consumer representatives gathered at the Spring meeting of the NAIC
Greater Than the Sum
April is National Minority Health Month and it is more important than ever to raise awareness about health disparities that continue to affect the health of millions of Americans.
Paying for Delay – Putting Consumers in the Crosshairs
Reposted from the Community Catalyst blog Health Policy Hub ....
As we discussed here last week, the U.S. Supreme Court is currently deliberating over whether pharmaceutical companies can collude to reap $3.5 billion a year in excess profits from American
Paying for Delay – Putting Consumers in the Crosshairs
As we discussed here last week, the U.S. Supreme Court is currently deliberating over whether pharmaceutical companies can collude to reap $3.5 billion a year in excess profits from American patients.